GreenLight Biosciences and Samsung Biologics have signed an agreement to collaborate on the production of ribonucleic acid (mRNA)-based vaccines against Covid-19. It is intended to accelerate the production of a candidate vaccine needed for Phase III clinical trials and commercial sale after regulatory approval.
Samsung Biologics is currently working on plans to implement the mRNA-based mRNA vaccine drug substance manufacturing expertise at its plant in Songdo, South Korea, which is expected to begin operations early next year.
Both companies say they are committed to making vaccines available to everyone, not just citizens of developed countries. This is in line with calls by the Coalition for Epidemic Preparedness Innovation (CEPI) and other organizations to increase production capacity worldwide for vaccines against other infectious diseases.
